Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,401
archived clinical trials in
Alzheimer Disease

12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US003
mi
from
Orlando, FL
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US003
mi
from
Orlando, FL
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US004
mi
from
The Villages, FL
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US004
mi
from
The Villages, FL
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US049
mi
from
Brooklyn, NY
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US049
mi
from
Brooklyn, NY
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US119
mi
from
Shaker Heights, OH
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US119
mi
from
Shaker Heights, OH
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US162
mi
from
Plains, PA
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US162
mi
from
Plains, PA
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US096
mi
from
Rancho Mirage, CA
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US096
mi
from
Rancho Mirage, CA
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US179
mi
from
Hamden, CT
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US179
mi
from
Hamden, CT
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US110
mi
from
Miami, FL
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US110
mi
from
Miami, FL
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US172
mi
from
North Palm Beach, FL
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US172
mi
from
North Palm Beach, FL
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US048
mi
from
Atlanta, GA
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US048
mi
from
Atlanta, GA
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US046
mi
from
Atlanta, GA
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US046
mi
from
Atlanta, GA
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US217
mi
from
Columbus, GA
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US217
mi
from
Columbus, GA
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US116
mi
from
Newton, MA
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US116
mi
from
Newton, MA
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US174
mi
from
Quincy, MA
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US174
mi
from
Quincy, MA
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US094
mi
from
Las Vegas, NV
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US094
mi
from
Las Vegas, NV
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US135
mi
from
Berlin, NJ
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US135
mi
from
Berlin, NJ
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US209
mi
from
Toms River, NJ
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US209
mi
from
Toms River, NJ
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US036
mi
from
West Long Branch, NJ
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US036
mi
from
West Long Branch, NJ
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US097
mi
from
New Hyde Park, NY
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US097
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US185
mi
from
Charlotte, NC
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US185
mi
from
Charlotte, NC
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US008
mi
from
Cincinnati, OH
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US008
mi
from
Cincinnati, OH
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US134
mi
from
Portland, OR
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US134
mi
from
Portland, OR
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US169
mi
from
Media, PA
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US169
mi
from
Media, PA
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US143
mi
from
Orem, UT
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US143
mi
from
Orem, UT
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US170
mi
from
Spokane, WA
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US170
mi
from
Spokane, WA
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US220
mi
from
Tucson, AZ
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US220
mi
from
Tucson, AZ
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US037
mi
from
Tampa, FL
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US037
mi
from
Tampa, FL
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US042
mi
from
Tampa, FL
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US042
mi
from
Tampa, FL
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US095
mi
from
Shreveport, LA
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US095
mi
from
Shreveport, LA
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US215
mi
from
Mount Arlington, NJ
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US215
mi
from
Mount Arlington, NJ
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US113
mi
from
Cleveland, OH
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US113
mi
from
Cleveland, OH
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US148
mi
from
Willow Grove, PA
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US148
mi
from
Willow Grove, PA
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US043
mi
from
San Antonio, TX
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US043
mi
from
San Antonio, TX
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US149
mi
from
Charlottesville, VA
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US149
mi
from
Charlottesville, VA
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US256
mi
from
Pensacola, FL
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US256
mi
from
Pensacola, FL
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US144
mi
from
Hattiesburg, MS
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US144
mi
from
Hattiesburg, MS
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US197
mi
from
Lawrenceville, NJ
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US197
mi
from
Lawrenceville, NJ
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US150
mi
from
Chapel Hill, NC
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US150
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US111
mi
from
Baton Rouge, LA
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US111
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
AR130
mi
from
La Plata,
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
AR130
mi
from
La Plata,
Click here to add this to my saved trials
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  3/16/2018
US057
mi
from
Manchester, NJ
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 3/16/2018
US057
mi
from
Manchester, NJ
Click here to add this to my saved trials
Human Brain Antioxidants During Oxidative Stress
Noninvasive Antioxidant Quantification in the Human Brain Under Oxidative Stress
Status: Enrolling
Updated:  3/20/2018
Univ of Minnesota
mi
from
Minneapolis, MN
Human Brain Antioxidants During Oxidative Stress
Noninvasive Antioxidant Quantification in the Human Brain Under Oxidative Stress
Status: Enrolling
Updated: 3/20/2018
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Human Brain Antioxidants During Oxidative Stress
Noninvasive Antioxidant Quantification in the Human Brain Under Oxidative Stress
Status: Enrolling
Updated:  3/20/2018
Univ of Minnesota
mi
from
Minneapolis, MN
Human Brain Antioxidants During Oxidative Stress
Noninvasive Antioxidant Quantification in the Human Brain Under Oxidative Stress
Status: Enrolling
Updated: 3/20/2018
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Improving Function, Quality of Life, Glycemia in Diabetics With Dementia
Improving Function, Quality of Life, Glycemia in Diabetics With Dementia
Status: Enrolling
Updated:  3/27/2018
Veterans Affairs Medical Center
mi
from
Omaha, NE
Improving Function, Quality of Life, Glycemia in Diabetics With Dementia
Improving Function, Quality of Life, Glycemia in Diabetics With Dementia
Status: Enrolling
Updated: 3/27/2018
Veterans Affairs Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Improving Function, Quality of Life, Glycemia in Diabetics With Dementia
Improving Function, Quality of Life, Glycemia in Diabetics With Dementia
Status: Enrolling
Updated:  3/27/2018
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Improving Function, Quality of Life, Glycemia in Diabetics With Dementia
Improving Function, Quality of Life, Glycemia in Diabetics With Dementia
Status: Enrolling
Updated: 3/27/2018
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants
A Phase 1 Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Oral Doses of TAK-071 in Healthy Subjects and Subjects With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability and Food Effect of TAK-071 in Healthy Subjects
Status: Enrolling
Updated:  3/27/2018
Clinical Research Facility
mi
from
Glendale, CA
Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants
A Phase 1 Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Oral Doses of TAK-071 in Healthy Subjects and Subjects With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability and Food Effect of TAK-071 in Healthy Subjects
Status: Enrolling
Updated: 3/27/2018
Clinical Research Facility
mi
from
Glendale, CA
Click here to add this to my saved trials
Telomerase Activator and Retinal Amyloid
Evaluation of an Oral Telomerase Activator on Retinal Amyloid
Status: Enrolling
Updated:  3/29/2018
CHippewa Valley Eye Clinic
mi
from
Eau Claire, WI
Telomerase Activator and Retinal Amyloid
Evaluation of an Oral Telomerase Activator on Retinal Amyloid
Status: Enrolling
Updated: 3/29/2018
CHippewa Valley Eye Clinic
mi
from
Eau Claire, WI
Click here to add this to my saved trials
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated:  4/2/2018
Banner Alzheimer'S Institute
mi
from
Phoenix, AZ
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated: 4/2/2018
Banner Alzheimer'S Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated:  4/2/2018
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated: 4/2/2018
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated:  4/2/2018
Xenoscience Inc.
mi
from
Phoenix, AZ
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated: 4/2/2018
Xenoscience Inc.
mi
from
Phoenix, AZ
Click here to add this to my saved trials